Abstract: Continuous pursuit of predictive and ethical drug testing systems has driven convergence between the fields of biotechnology and engineering. Emerging Modalities The preclinical research field has been significantly shaped by 3D bioprinting and various organoid platforms. These technologies pretend the native tissue architecture, cell interactions and physiological microenvironments to a much greater extent than the traditional two-dimensional (2D) cultures or animal models. 3D bioprinting allows for the layer-by-layer assembly of living tissues using bioinks that contain cells and biomaterials, whereas organoids, stem cell-derived self-organized mini-organs, can recreate a range of human physiological functions. Together, they have made amazing improvements in the accuracy of predicting drug activity, toxicity and metabolism, pushing us toward personalized therapeutics. This paper focuses on the development, rationale, and pharmaceutical use of bio printed organoid systems as well as provides overview of current challenges, ethical considerations and regulatory viewpoints. The fusion of AI, microfluidics and omics technologies is envisioned to evolve these platforms into autonomous patient-specific drug discovery ecosystems for the next era of precision medicine.

Keywords: 3D bioprinting, organoids, drug testing, pharmacology, tissue engineering, personalized medicine, regenerative pharmaceutics

Downloads: | DOI: 10.17148/IARJSET.2025.121229